Novo Nordisk
Produced Novo Nordisk A / S and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a world leader in diabetes pharmaceuticals sector. In this area, the company also has the broadest product range in the industry. Even in the areas of blood clotting medications, growth hormone therapy and hormone replacement therapy, the company is represented.
Group Overview
Novo Nordisk is divided into a holding company, Novo Group, under which the company Novo Nordisk A / S, Novozymes A / S and Novo A / S are located. The company has two main business areas:
- Diabetes medications and
- Hormone preparations
In addition, the company develops and sells also different types of enzymes that are used for example in the food industry, in wastewater treatment or purification. The main plant of the company lies in the Danish Bagsvaerd, in Greater Copenhagen. In addition to its headquarters in Denmark, Novo Nordisk still manufacturing facilities in six other countries, as well as agencies or offices in 79 countries. The Germany office is located, since August 1958 in Mainz.
Novo Nordisk awards since 2002, endowed with 12,000 euros Novo Nordisk Media Prize for journalistic articles about diabetes.
Ownership structure
All A- and B- shares in Novo Nordisk A / S since 31 December 1999, the unlisted Novo A / S, which is in turn owned by the Novo Nordisk Foundation belong. The Novo Nordisk Foundation is a nonprofit foundation whose goal is to provide a stable base for the company in the Novo Nordisk Group is available, as well as to participate in the scientific, humanitarian and social progress. The A and B shares representing 25.5 % of the total share capital and 68.5 % of the vote. This means that the Novo A / S at the Annual Meeting always has the majority of votes.
History
Novo Nordisk was created in 1989 through the merger of two Danish companies Novo Industri A / S and Nordisk Gentofte A / S.